Avaleht/Aktsiad/AIM

AIM

USD

AIM ImmunoTech Inc. Common Stock

$1.600-0.400 (-20.000%)

Reaalajas hind

Healthcare

Biotehnoloogia

Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$2.000

Kõrge

$2.020

Madal

$1.570

Maht

0.10M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

4.4M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

0.10M

Börs

ASE

Valuuta

USD

52 nädala vahemik

Madal $1.57Praegune $1.600Kõrge $36

Seotud uudised

4. nov 2025 · 14:05

GlobeNewswire

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical

Vaata rohkem

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

3. nov 2025 · 13:55

GlobeNewswire

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the European Patent Office has officially granted AIM's European Patent No. 4,096,675, titled

Vaata rohkem